DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Phase 2

Completed

Conditions: Acute Gout

Interventions: Drug: Canakinumab
Drug: Triamcinolone acetonide

First Posted Date: 2008-11-26

Last Posted Date: 2012-04-10

Lead Sponsor: Novartis

Target Recruit Count: 200

Registration Number: NCT00798369

Locations: 🇺🇸
Montana Medical Research, Missoula, Montana, United States
🇺🇸
Northwest Clinical Trials, Boise, Idaho, United States
🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom

and more 26 locations

Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: hydrochlorothiazide
Drug: Aliskiren

First Posted Date: 2008-11-25

Last Posted Date: 2011-10-17

Lead Sponsor: Novartis

Target Recruit Count: 1254

Registration Number: NCT00797862

Locations: 🇻🇪
Investigative Site, Caracas, Venezuela

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Hydrochlorothiazide

First Posted Date: 2008-11-25

Last Posted Date: 2011-03-11

Lead Sponsor: Novartis

Target Recruit Count: 532

Registration Number: NCT00797316

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: CAD106
Biological: Placebo

First Posted Date: 2008-11-21

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 31

Registration Number: NCT00795418

Locations: 🇺🇸
NOCCR Knoxville, Knoxville, Tennessee, United States
🇺🇸
ATP Clinical Research, Costa Mesa, California, United States
🇺🇸
Alpine Clinical Research Center, Boulder, Colorado, United States

and more 7 locations

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

Phase 4

Completed

Conditions: Hypertension
Diabetes Mellitus

Interventions: Drug: Hydrochlorothiazide (HCTZ)
Drug: Amlodipine
Drug: Aliskiren

First Posted Date: 2008-11-07

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis

Target Recruit Count: 860

Registration Number: NCT00787605

Locations: 🇺🇸
Sites in USA, East Hanover, New Jersey, United States

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: FTY720

First Posted Date: 2008-11-05

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 36

Registration Number: NCT00785083

Locations: 🇬🇧
Novartis Investigator Site, Manchester, United Kingdom

A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: QAV680
Drug: Mometasone Furoate

First Posted Date: 2008-11-04

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 44

Registration Number: NCT00784732

Locations: 🇨🇦
Novartis Investigator Site, Toronto, Canada

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine 10 mg
Drug: Aliskiren 150
Drug: Amlodipine 300

First Posted Date: 2008-10-24

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis

Target Recruit Count: 847

Registration Number: NCT00778921

Locations: 🇹🇷
Investigative Site, Ankara, Turkey

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren/Amlodipine 300/5 mg
Drug: Aliskiren/Amlodipine 300/10 mg
Drug: Aliskiren 300 mg
Drug: Placebo to Aliskiren
Drug: Placebo to Aliskiren/Amlodipine

First Posted Date: 2008-10-22

Last Posted Date: 2011-07-12

Lead Sponsor: Novartis

Target Recruit Count: 818

Registration Number: NCT00777946

Locations: 🇻🇪
Investigative Site, Venezuela, Venezuela
🇮🇹
Investigative site, Italy, Italy

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren Hydrochlorothiazide
Drug: Ramipril

First Posted Date: 2008-10-15

Last Posted Date: 2011-03-11

Lead Sponsor: Novartis

Target Recruit Count: 386

Registration Number: NCT00772577

Locations: 🇺🇸
Investigative Site, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy